Doximity's Q4 2026 Earnings Prompt Downgrade Wave, BofA Cuts Target to $38

Why It Matters

The downgrade wave around Doximity illustrates the heightened scrutiny on AI‑heavy growth strategies in the digital‑health sector. Investors are demanding concrete evidence that spending on tools like DoxGPT will translate into sustainable top‑line expansion, and the rapid price‑target cuts signal a low tolerance for execution risk. The episode also serves as a bellwether for other health‑tech firms that are scaling AI capabilities, highlighting the importance of transparent guidance and measurable milestones. For the broader earnings‑call landscape, Doximity’s case shows how a single guidance miss can cascade into a multi‑bank downgrade, amplifying volatility and reshaping market expectations. The reaction may prompt analysts to adopt more conservative forward‑looking models for AI‑centric companies, potentially tightening valuation multiples across the sector.

Key Takeaways

• Doximity reported Q4 2026 revenue of $145.4 million, up 5% YoY, and posted record $107 million free cash flow.
• FY 2027 revenue guidance of $664‑$676 million (3%‑5% growth) fell short of consensus near $697 million.
• BofA cut its price target to $38 from $47, citing "less visibility into growth and elevated execution risk".
• More than ten Wall Street firms downgraded Doximity, with targets ranging from $18 to $35.
• Shares fell about 24% on May 14 and are down over 45% year‑to‑date.

Pulse Analysis

Doximity’s earnings release arrived at a moment when the market is increasingly skeptical of AI‑driven growth narratives. The company’s decision to label fiscal 2027 an “AI investment year” signals a willingness to burn cash now for future payoff, but the lack of near‑term revenue visibility has eroded confidence. BofA’s revised EV/EBITDA multiple—down to 20x—places Doximity on the lower end of the digital‑health valuation spectrum, suggesting that analysts now price the stock as a cash‑flow play rather than a high‑growth AI story.

The downgrade cascade also reflects a broader shift in analyst methodology. In the past, firms often tolerated aggressive AI spend with generous forward‑looking multiples. Post‑Doximity, we may see a tightening of assumptions, especially for companies that have yet to demonstrate monetization of AI tools. This could compress valuations across the sector, prompting management teams to provide more granular roadmaps and interim performance metrics.

Going forward, Doximity’s ability to convert its AI investments into incremental revenue will be the litmus test for its valuation recovery. If DoxGPT or related offerings begin to lift gross margins or drive new user acquisition, the price‑target cuts could be reversed, and the stock may regain some of its lost ground. Conversely, continued uncertainty around AI monetization could keep the stock under pressure, reinforcing the market’s new, more cautious stance on health‑tech growth bets.